Drug Trial Radar · NCT06568471
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Nov 16, 2024
Primary completion
Feb 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Hasten Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \[≤31 days\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.
Conditions
- Hypercholesterolemia
- Dyslipidemias
- Primary Hypercholesterolemia
- Heterozygous Familial Hypercholesterolemia
- Hyperlipidemia; Mixed
- Metabolic Disease
- ASCVD
Interventions
LerodalcibepDrug
PCSK9 inhibitor
matching placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C change compared to PlaceboTime frame: 12 weeks
- Mean LDL-C change at Weeks 10 and 12 compared to PlaceboTime frame: 12 weeks
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Not yet recruiting
Beijing Anzhen Hospital of Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Luhe Hospital, Capital Medical Univeristy
Beijing, Beijing Municipality, China · Recruiting
Beijing Tsinghua Changgeng Hospital
Beijing, Beijing Municipality, China · Recruiting
Fuwai Hospital, CAMS & PUMC
Beijing, Beijing Municipality, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Shijiazhuang People's Hospital
Shijiazhuang, Hebei, China · Recruiting
Daqingshi People's Hospital
Daqing, Heilingjiang, China · Recruiting
The 2nd Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Nanchang People's Hospital
Nanchang, Jiangxi, China · Recruiting
Binzhou Medical University Hospital
Binzhou, Shandong, China · Recruiting
Heze Municipal Hospital
Heze, Shandong, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Zibo Municipal Hospital
Zibo, Shandong, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical Univesity
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.